The Menopause Symptom Doctors Finally Wrote Guidelines For — and Why It's Not Just 'Dryness'

Most women know about hot flashes. Far fewer know about the symptom that makes sex painful, urination frequent, and infections repeat — and that doctors only named "genitourinary syndrome of menopause" in 2014. In 2025 it finally got its first real guideline, and the evidence is bigger than discomfort.

Key Takeaways

• The American Urological Association released the first-ever GSM guideline in April 2025, giving clinicians 26 evidence-based statements for a long-under-addressed condition (AUA, 2025).
• GSM describes vaginal, urinary, and sexual symptoms from falling estrogen; it affects millions of postmenopausal women and is under-diagnosed (AUA, 2025).
• Vaginal estrogen is linked in clinical commentary to fewer urinary tract infections, hospitalizations, and even sepsis-related deaths (AUA expert commentary, 2025).
• Treatment is not just "lubricant" — it includes low-dose vaginal estrogen, moisturizers, and laser or other options per guideline (AUA, 2025).

What Is GSM and Why Was It Ignored?

Genitourinary syndrome of menopause is the cluster of symptoms and physical changes from declining estrogen in the vaginal and urinary tissues — dryness, burning, pain with sex, urgency, and recurrent UTI (AUA, 2025). It was named only in 2014, and until the 2025 guideline there was no consensus on how many symptoms or signs qualified for diagnosis. Because it sits at the crossroads of urology and gynecology, it fell between specialties and was historically minimized as "a little dryness."

Citation capsule: GSM bundles vaginal, urinary, and sexual symptoms driven by estrogen loss and affected millions of postmenopausal women, yet lacked diagnostic consensus until the AUA's first guideline in 2025 (AUA, 2025).

This gap is why our perimenopause brain fog and 3am waking articles rarely mention it — the field itself under-talked it.

Why Did a Guideline Matter in 2025?

Before 2025 there was no formal playbook, so diagnosis and treatment varied wildly. The AUA guideline's 26 statements give clinicians standardized criteria and treatment paths for the first time (AUA, 2025). Experts framed it as potentially life-saving because untreated GSM is not merely uncomfortable — it is associated with urinary infections that can escalate. One clinician noted data linking vaginal estrogen use to reduced sepsis, mortality, and hospitalization (AUA expert commentary, 2025).

Citation capsule: The 2025 AUA guideline provided the first standardized diagnosis and treatment framework for GSM, with experts arguing that vaginal estrogen's link to fewer UTIs, hospitalizations, and sepsis deaths makes the condition a serious medical issue, not a cosmetic one (AUA, 2025).

Our HRT black-box removal article shows the broader hormone-therapy shift this sits within.

How Is GSM Treated?

First-line is usually low-dose vaginal estrogen — creams, rings, or tablets — which restores tissue health locally with minimal systemic absorption (AUA, 2025). Non-hormonal moisturizers and lubricants help symptoms, and other options including laser therapy exist for selected patients per guideline. The key is that "use more lube" is not the treatment; addressing the underlying tissue change is.

Citation capsule: Guideline care for GSM centers on low-dose vaginal estrogen to reverse tissue changes, supported by moisturizers and selected other therapies, rather than symptom-cover alone (AUA, 2025).

Women comparing systemic vs local hormones should also read estrogen and perimenopause risk.

Who Should Bring This Up With a Clinic?

Any woman with vaginal dryness, pain with sex, new urinary urgency, or repeat UTIs after menopause should raise GSM specifically, because clinicians may not ask (AUA, 2025). It is common, treatable, and distinct from hot flashes — many women have one without the other. Our waking at 3am and menopausal weight gain articles cover other midlife changes, but GSM deserves its own conversation.

Citation capsule: Women with post-menopausal dryness, painful sex, urgency, or recurrent UTI should name GSM directly, since under-asking by both sides leaves a common, treatable condition unmanaged (AUA, 2025).

Frequently Asked Questions

Is GSM the same as normal dryness?

No. GSM is a syndrome of vaginal, urinary, and sexual tissue changes from estrogen loss, not just temporary dryness (AUA, 2025).

Does vaginal estrogen enter the bloodstream?

Low-dose vaginal forms have minimal systemic absorption, which is why they are distinguished from systemic hormone therapy (AUA, 2025).

Can it prevent infections?

Clinical commentary links vaginal estrogen to fewer UTIs and fewer severe infections, though it is not a guarantee (AUA, 2025).

Is it covered by the HRT label changes?

Partly — Estring (vaginal estrogen) was among the first products relabeled in 2026, but discuss your history with your clinician (FDA, 2026).

Conclusion

GSM is the menopause symptom most women have never been named, yet it drives pain, infection, and even hospitalization. The 2025 guideline finally gave it a diagnosis and a treatment path, and the data suggest vaginal estrogen does more than soothe — it may prevent serious infection. If you have the symptoms, say the name, and ask about low-dose local estrogen.

Sources

• American Urological Association. First-ever guideline on genitourinary syndrome of menopause. April 2025. Retrieved 2026-08-11. https://www.auanet.org/
• AUA expert commentary on GSM, vaginal estrogen, and infection outcomes, 2025. Retrieved 2026-08-11.